Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3819469 in Adults With Elevated Lipoprotein(a)
CTR20230125Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lepodisiran in cardiac morbidity, sponsored by Eli Lilly and Company. Started Jan 2023; status: completed.
02
Drugs
lepodisiran
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on CTR20230125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230125.